Pyrotinib for advanced HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how well the drug pyrotinib works in people with advanced breast cancer that has spread and tests positive for HER2. HER2 is a protein that can make cancer cells grow, and pyrotinib targets it. If you have this type of breast cancer, this study may show if the treatment helps you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with HER2-positive breast cancer that cannot be removed with surgery or has spread to other parts of the body.
- Your cancer has been tested and found to be HER2-positive (either by a standard test called IHC showing 3+ or another test called ISH showing positive).
- You are willing to take part in the study and follow the doctor's instructions, including coming to follow-up visits.
- You must not have other types of cancer (except for cured skin cancer or cervical cancer).
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
This study tests giving certain targeted drugs before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach helps reduce tumor size and improve outcomes.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.